| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA509:Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
|
Medicine details |
|
| Medicine name | pertuzumab (Perjeta®) |
| Formulation | 420 mg concentrate for solution for infusion |
| Reference number | 684 |
| Indication | In combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 16/05/2013 |
| NICE guidance | TA509:Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |